COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional StudyArticle Published on 2021-12-312022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] addition age biologic biologics BMI BNT162b2 Care ChAdOx1 nCoV-19 conducted COVID-19 COVID-19 vaccination COVID-19 vaccine Crohn’s disease cross-sectional death diagnosed effective Efficacy enrolled evaluate Expatriate Express female gastroenterology General population Health Organization Hesitancy Hospitalization IBD Inflammatory bowel disease infliximab Kuwait male median age no statistical difference Patient patients physician Prevalence prevalence of COVID-19 Primary outcome receive receiving recruitment reducing retrieved risk Safe secondary outcome Severe infection Sex shown single-center the vaccine Therapies therapy ulcerative colitis vaccination Vaccine vedolizumab WHO [DOI] 10.3390/vaccines10010055 PMC 바로가기 [Article Type] Article
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease CareSupplement Articles Published on 2021-12-262022-10-29 Journal: Journal of the Canadian Association of Gastroenterology [Category] COVID-19, [키워드] Canada Care COVID-19 delivery determine Effectiveness Efficiency evaluate exacerbated feasibility feasible Future Health health care delivery health care need IBD Impact implementation IMPROVE individual Inflammatory bowel disease majority medications Model pandemic public health Quality of life Rapid required SARS-CoV-2 pandemic shown synchronous Telemedicine Virtual care widespread [DOI] 10.1093/jcag/gwab034 PMC 바로가기 [Article Type] Supplement Articles
Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysisMeta-Analysis Published on 2021-12-232024-09-04 Journal: Therapeutic Advances in Gastroenterology [Category] 대상포진, [키워드] clinical trials IBD JAKi new therapies Real-world evidence [DOI] 10.1177/17562848211064004 PMC 바로가기 [Article Type] Meta-Analysis
Acceptance of COVID-19 Vaccines among Patients with Inflammatory Bowel Disease in JapanArticle Published on 2021-12-222022-10-31 Journal: International journal for equity in health [Category] COVID-19, [키워드] 95% confidence interval acceptance age appear AZD1222 BNT162b2 Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccine disease evaluated Factor hesitancy rate IBD immunomodulator independent Inflammatory bowel disease Japan Japanese less Logistic regression analysis measure mRNA-1273 Odds ratio Participants Patient patients questionnaire retrospective cohort study risk of COVID-19 severe acute respiratory syndrome coronavirus 2 surveys and questionnaires vaccination vaccination rates Vaccine Vaccine hesitancy vaccine-hesitant vedolizumab was performed [DOI] 10.3390/healthcare10010006 PMC 바로가기 [Article Type] Article
The physiological and psychological effects of cognitive behavior therapy on patients with inflammatory bowel disease before COVID-19: a systematic reviewResearch Published on 2021-12-152022-10-27 Journal: BMC Gastroenterology [Category] Coronavirus, Fulltext, SARS, [키워드] Anxiety C-reactive protein CBT CINAHL clinical trial cognitive Cognitive behavior therapy cognitive behavioral therapy Consensus Crohn's disease Depression Disease activity Effect eligible evaluate Evidence IBD IMPROVE inclusion criteria Inflammatory bowel disease initial Mental objective outcome Patient patients physical physiological positive post-intervention Psychological psychological improvement PsycINFO Quality of life Randomized controlled trial RCT reduce Result searched shown supplementary material sustained systematic review therapy Treatment ulcerative colitis Web of Science [DOI] 10.1186/s12876-021-02003-0 PMC 바로가기 [Article Type] Research
Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic TherapiesArticle Published on 2021-12-132022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] adalimumab age anti-SARS-CoV-2 anti-SARS-CoV-2 IgG antibody biologic biologic therapies BNT162b2 BNT162b2 vaccine ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine Concentration COVID-19 Crohn’s disease dose effective enrolled evaluate first dose follow-up study IBD immunogenicity Inflammatory bowel disease infliximab majority neutralizing antibody occur of BNT162b2 Patient performed positive proportion Prospective Study receiving response SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 vaccination SARS-CoV-2 vaccine second dose seroconverted serological response the vaccine Therapies therapy treated ulcerative colitis ustekinumab vaccination Vaccine Vaccines vedolizumbab [DOI] 10.3390/vaccines9121471 PMC 바로가기 [Article Type] Article
Impact of the Lockdown Due to the COVID-19 Pandemic on Patients With Inflammatory Bowel DiseaseMedicine Published on 2021-12-102022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] 95% CI Active disease affected age Analysis bowel conducted coronavirus disease COVID-19 COVID-19 pandemic Crohn's disease disease Disease activity disorder Effect Enrollment environmental factors exacerbated Factor Follow-up Government hospital IBD illnesses Impact Improving independent Inflammatory bowel disease intestinal Japan lockdown Logistic regression analysis management Mental multivariate Odds ratio outcome pandemic Patient patients Psychological questionnaire reported sleep quality Stress subsequent ulcerative colitis worsened [DOI] 10.3389/fmed.2021.649759 PMC 바로가기 [Article Type] Medicine
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Mental Health and Quality of LifeSupplement Articles Published on 2021-12-052022-10-29 Journal: Journal of the Canadian Association of Gastroenterology [Category] COVID-19, [키워드] addition anxiety symptom Care Community concern contribute controls coronavirus coronavirus disease COVID-19 COVID-19 pandemic Crohn’s disease Depression Depressive symptoms detrimental disease distress doubling elevated Evolution Factor General population Health highest Hospitalization IBD Impact impairment IMPROVE include increased risk independent of infecting Inflammatory bowel disease life lowest Mental mental health mental health conditions Mortality MOST National outcome pandemic prevalent psychologic Quality Quality of life reduced reduction in risk SARS-CoV-2 shown suffered Treatment ulcerative colitis Uncertainty while women [DOI] 10.1093/jcag/gwab031 PMC 바로가기 [Article Type] Supplement Articles
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Children and Expectant Mothers With Inflammatory Bowel DiseaseSupplement Articles Published on 2021-12-052022-10-29 Journal: Journal of the Canadian Association of Gastroenterology [Category] COVID-19, [키워드] acute respiratory syndrome affected Anxiety Care children coronavirus Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) Corticosteroids COVID-19 COVID-19 severity Crohn’s disease death Depression Disease activity effort Epidemiology examined global pandemic group hospital IBD Impact increased risk Inflammation Inflammatory bowel disease less manifestation Manifestations measure medication mental health mild infection Older pandemic pediatrics Pregnancy pregnant preterm delivery Protective provided reduce required resulting SARS-CoV-2 severe COVID-19 significantly ulcerative colitis vaccination [DOI] 10.1093/jcag/gwab030 PMC 바로가기 [Article Type] Supplement Articles
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Risk Factors and MedicationsSupplement Articles Published on 2021-12-052022-10-29 Journal: Journal of the Canadian Association of Gastroenterology [Category] COVID-19, [키워드] advanced age adverse outcomes Affect Alter biologics bowel Canada Collaborative effort Community complications of COVID-19 coronavirus disease Corticosteroids Course COVID-19 death disease dysregulation Factor General population IBD immune response immune system Impact imperative Infection Inflammatory bowel disease Lung disease medication medications notable Person public health recommendation reduce Research risk risk factor Risk factors serious complication smoking therapy use of corticosteroid [DOI] 10.1093/jcag/gwab032 PMC 바로가기 [Article Type] Supplement Articles